Abstract
Triple-negative breast cancer (TNBC), which accounts for approximately 10% to 15% of breast cancers, remains the most aggressive subtype and is characterized by early disease relapse for a subset of patients. TNBC remains a clinical challenge, given the lack of effective targeted treatments such as endocrine therapy for hormone receptor-positive (HR+) tumors or therapies against HER2.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Biomarkers, Tumor / genetics
-
Biomarkers, Tumor / metabolism
-
Chemotherapy, Adjuvant
-
Female
-
Humans
-
Immunotherapy
-
Neoadjuvant Therapy
-
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use*
-
Treatment Outcome
-
Triple Negative Breast Neoplasms / drug therapy*
-
Triple Negative Breast Neoplasms / genetics
-
Triple Negative Breast Neoplasms / metabolism
-
Triple Negative Breast Neoplasms / pathology
Substances
-
Biomarkers, Tumor
-
Poly(ADP-ribose) Polymerase Inhibitors